The Effect of Heparin vs. Citrate on the Interaction of Platelets with Vascular Graft Materials

Kandice Kottke-Marchant; James M Anderson; Albert Rabinovitch; Richard A Huskey; Roger Herzig

doi:10.1055/s-0038-1660145

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 54(04): 842-848
DOI: 10.1055/s-0038-1660145

Original Article

Schattauer GmbH Stuttgart

The Effect of Heparin vs. Citrate on the Interaction of Platelets with Vascular Graft Materials

Authors

Kandice Kottke-Marchant

The Departments of Macromolecular Science and Pathology, Case Western Reserve University, Cleveland, Ohio, USA
James M Anderson

The Departments of Macromolecular Science and Pathology, Case Western Reserve University, Cleveland, Ohio, USA
Albert Rabinovitch

The Departments of Macromolecular Science and Pathology, Case Western Reserve University, Cleveland, Ohio, USA
Richard A Huskey

The Departments of Macromolecular Science and Pathology, Case Western Reserve University, Cleveland, Ohio, USA
Roger Herzig

The Departments of Macromolecular Science and Pathology, Case Western Reserve University, Cleveland, Ohio, USA

Abstract

PDF Download

Summary

Heparin is known to affect platelet function in vitro, but little is known about the effect of heparin on the interaction of platelets with polymer surfaces in general, and vascular graft materials in particular. For this reason, the effect of heparin vs. citrate anticoagulation on the interaction of platelets with the vascular graft materials expanded polytetrafluoroethylene (ePTFE), Dacron Bionit (DB) and preclotted Dacron Bionit (DB/PC) was studied in a recirculating, in vitro perfusion system. Platelet activation, as shown by a decrease in platelet count, an increase in platelet release and a decrease in platelet aggregation, was observed for all vascular graft materials tested using heparin and was greater for Dacron and preclotted Dacron than for ePTFE. Significant differences between heparin and citrate anticoagulation were seen for platelet release, platelet aggregation and the relative ranking of material platelet-reactivity. However, the trends and time course of platelet activation were similar with both heparin and citrate for the materials tested.

Key words

Platelet activation - Vascular grafts - Effect of anticoagulation - In vitro perfusion system

PDF (1395 kb)

References

References
1 Addonizio Jr VP, Macarak EJ, Nicolaou KC, Edmunds Jr LH, Colman RW. Effects of prostacyclin and albumin on platelet loss during in vitro simulation of extracorporeal circulation. Blood 1979; 53: 1033-1042
2 Hamlin GW, Rajah SM, Crow MJ, Kester RC. Evaluation of the thrombogenic potential of three types of arterial graft studied in an artificial circulation. Br J Surg 1978; 65: 272-276
3 Thomson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Molec Med 1973; 45: 485-494
4 O’Brien JR, Shoobridge SM, Finch WJ. Comparison of the effect of heparin and citrate on platelet aggregation. J Clin Pathol 1969; 22: 28-31
5 Moolten SE, Vroman L, Vroman GM S, Goodman B. Role of blood platelets in thromboembolism. Arch Intern Med 1949; 84: 667-710
6 Lindsay RM, Rourke JT B, Reid BD, Linton AL, Gilchrist T, Courtney J, Edwards RO. The role of heparin on plateletretention by acrylonitrile co-polymer dialysis membranes. J Lab Clin Med 1977; 89: 724-734
7 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
8 MacIntyre DE, Handin RI, Rosenberg R, Salzman EW. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. Thromb Res 1981; 22: 167-175
9 Bertele V, Roncaglioni MC, Donati MB, de Gaetano G. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation. Thromb Haemostas 1983; 49: 81-83
10 Flicker W, Milthorpe BK, Schindhelm K, Odell RA, McPherson J, Farrell PC. Platelet factor release following heparin administration and during extracorporeal circulation. Trans Am Soc Artif Intern Organs 1982; 28: 431-436
11 Ludlam CA, Cash JD. Studies on the liberation of p-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
12 Goldman M, Gunson B, Hawker RJ, McCollum CN. Human umbilical vein and polytetrafluoroethylene arterial grafts compared in an artificial circulation. Br J Surg 1983; 70: 4-6
13 McCollum CN, Crow MJ, Rajah SM, Kester RC. Antithrombotic therapy for vascular prostheses: an experimental model testing platelet inhibitory drugs. Surgery 1980; 87: 668-676
14 Clagett GP, Graeber GM, Robinowitz M, Langloss JM, Ram well PW. Differentiation of vascular prostheses in dogs with serial tests of in vivo platelet reactivity. Surgery 1984; 95: 331-338
15 Pumphrey CW, Cheseboro JH, Dewanjee MK, Wahner HW, Hollier LH, Pairolero PC, Fuster V. In vivo quantitation of platelet deposition on human arterial bypass grafts using indium-Ill-labeled platelets: effect of dipyridamole and aspirin. Am J Cardiol 1983; 51: 796-801
16 Kottke-Marchant K. The in vitro blood compatibility of vascular graft materials. PhD Dissertation, Cleveland, Ohio, CaseWestern Reserve University, Cleveland 1985
17 Bowie EJ W, Owen Jr CA. Platelet retention procedures. In: Handbook Series in Clinical Laboratory Sciences, section I Schmidt RM. Ed Boca Raton, FL: CRC Press; 1979. 1 397-410
18 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
19 Newhouse P, Clark C. The quantitation of platelet aggregation. Platelet Function: Laboratory Evaluation and Clinical Application Triplett DA. Ed Am Soc Clin Pathol Inc; Chicago: 1978. pp 109-121
20 Salzman EW. Surface-induced platelet adhesion, aggregation and release. Ann NY Acad Sci 1977; 283: 114-127
21 Uchiyama S, Stropp JQ, Claypool DA, Didisheim P, Dewanjee MK. Filter bleeding time: A new in vitro test of hemostasis. I. Evaluation in normal and thrombocytopenicsubjects. Thromb Res 1983; 31: 99-105
22 Kenny DA, Berger K, Walker MW, Robel SB, Boguslavsky L, Ray LI, Lischko MM, Sauvage LR. Experimental comparison of the thrombogenicity of fibrin and PTFE flow surfaces. Ann Surg 1980; 191: 355-361
23 Guidoin RG, Gosselin C, Rouleau C, Hagop GH, Boulay J, Awad J. Preclotting of knitted Dacron prosthesis: a scanning electron microscope study. J Thorac Cardiovasc Surg 1975; 70: 152-162
24 Hennessy Jr VL, Hicks RE, Niewiarowski S, Edmunds Jr LH, Colman RW. Function of human platelets during extracorporeal circulation. Am J Physiol 1977; 232: H622-H628
25 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-540
26 Wallace HW, Brooks HA, Stein TP, Zimmerman W. The contribution of anticoagulants to platelet dysfunction with extracorporeal circulation. J Thorac Cardiovasc Surg 1976; 72: 73-78
27 Zucker MB. Effect of heparin on platelet function. Thrombos Diathes Haemorrh 1975; 33: 63-65
28 Rao AK, Niewiarowski S, James P, Holt JC, Harris M, Elfenbein B, Bastl C. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-1213
29 Hamlin GW, Rajah SM, Crow MJ, Kester RC. Evaluation of the thrombogenic potential of three types of arterial graft studied in an artificial circulation. Br J Surg 1978; 65: 272-276
30 Salzman EW, Deykin D, Shapir RM, Rosenberg R. Management of heparin therapy. N Engl J Med 1975; 292: 1046-1050